Form 4: AbCellera Biologics Director Acquires Shares Through Option Exercise
SEC Form 4
Director Michael R. Hayden reports acquisition of AbCellera Biologics shares through option exercise.
Summary
- On June 21, 2024, Michael R. Hayden, a director of AbCellera Biologics Inc., acquired 163,934 shares through the exercise of share options.
- The exercise price of the options was $2.94.
- Following the transaction, Hayden directly owns 660,979 common shares.
- The share options are exercisable from June 12, 2025, and expire on June 21, 2034.
Sentiment
Score: 6
Explanation: Neutral sentiment. This is a standard disclosure of a director exercising stock options. It doesn't inherently indicate positive or negative sentiment, but rather reflects a routine transaction.
Positives
- A director exercising options can be seen as a positive signal, indicating confidence in the company's future performance.
Future Outlook
NA
Industry Context
This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency regarding the ownership stakes of company directors.
Stakeholder Impact
- The transaction may have a minor positive impact on shareholder sentiment, as it indicates a director's confidence in the company.
Key Dates
| Date | Description |
|---|---|
| 06/21/2024 | Date of transaction: Director exercised share options. |
| 06/12/2025 | Share options become exercisable. |
| 06/21/2034 | Share options expiration date. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.